Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 7%
Buy 27%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care has demonstrated a solid revenue trajectory, with projected revenue increases reaching approximately $1.229 million by 2027. The firm's strategic growth is indicated by an expected return to positive new patient start (NPS) growth in the US, driven by increased conversions from multiple daily injections and improved pharmacy access. Additionally, revenue beat expectations due to significant traction in the pharmacy channel, alongside a noted increase in renewal shipments, contributing to robust overall financial performance.

Bears say

Tandem Diabetes Care has faced significant operating losses since its inception and does not provide assurance for sustained profitability, casting doubt on its future financial health. The company's outlook is further challenged by expectations of flat to slightly declining new patient starts in the U.S. market, coupled with potential risks from competitive pressures and the performance of new product launches like the Mobi pump. Additionally, the company reported a 4% year-over-year decline in U.S. pump shipments, along with lower growth and margins compared to industry peers, which exacerbates concerns over its profitability and market position.

TNDM has been analyzed by 15 analysts, with a consensus rating of Hold. 7% of analysts recommend a Strong Buy, 27% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Hold based on their latest research and market trends.

According to 15 analysts, TNDM has a Hold consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.